Novo Nordisk's Alhemo drug has been recommended for European approval as a treatment for hemophilia, the company said Friday.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to ...